



ALKEM

ALKEM LABORATORIES LIMITED

Enhancing Lives

Longer | Better | Fuller

Annual Report
2021-22

Corporate Information

BOARD OF DIRECTORS

Mr. Basudeo N. Singh
Executive Chairman

Mr. Sandeep Singh
Managing Director

Mr. Mritunjay Kumar Singh
Executive Director

Mrs. Madhurima Singh
Executive Director

Mr. Balmiki Prasad Singh
Executive Director

Mr. Sarvesh Singh
Executive Director

Mr. Arun Kumar Purwar
Independent Director

Mr. Ranjal Laxmana Shenoy
Independent Director

Mr. Narendra Kumar Aneja
Independent Director

Ms. Sangeeta Singh
Independent Director

Ms. Sudha Ravi
Independent Director

Dr. Dheeraj Sharma
Independent Director

KEY MANAGERIAL PERSONNEL

Mr. Rajesh Dubey
President – Finance and Chief Financial Officer

Mr. Manish Narang
President – Legal, Company Secretary and Compliance Officer

AUDITORS

M/s. B S R & Co. LLP,
Chartered Accountants

BANKERS

SBI Bank
HDFC Bank
Citi Bank
Bank of India
DBS Bank
Yes Bank
Kotak Mahindra Bank
HSBC Bank
Axis Bank
IDBI Bank
ICICI Bank
MUFJ Bank (Bank of Tokyo)
Emirates NBD
Shinhan Bank
Federal Bank
HDFC Limited (NBFC)
LIC Housing Finance
Canara Bank
Union Bank of India
Bank of Baroda

REGISTERED OFFICE

Alkem House, Senapati Bapat Marg,
Lower Parel, Mumbai - 400 013,
Maharashtra, India
CIN: L00305MH1973PLC174201
Telephone: +91 22 3982 9999
Fax: +91 22 2495 2955
Website: www.alkemlabs.com
Email: investors@alkem.com

REGISTRAR & SHARE TRANSFER AGENTS

M/s Link Intime India Private Limited
Unit: Alkem Laboratories Limited
C-101, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai - 400 083
Telephone: +91 22 4918 6270
Fax: +91 22 4918 6060
E-mail: rnt.helpdesk@linkintime.co.in
Website: www.linkintime.co.in

PLANT LOCATIONS

1. Daman, India
2. Mandva, Gujarat, India
3. Ankleshwar, Gujarat, India
4. Unit I Baddi, Himachal Pradesh, India
5. Kumrek, East Sikkim, India
6. Alkem Health Science, (Unit of the Company) Unit I, II & III, Samardung, South Sikkim, India
7. California, U.S.A.
8. Missouri, U.S.A.
9. Indchemie Health Specialities Private Limited, Somnath, Daman, India
10. Indchemie Health Specialities Private Limited, Amaliya, Daman, India
11. Indchemie Health Specialities Private Limited, Baddi, Himachal Pradesh, India
12. Unit I & II, Indchemie Health Specialities Private Limited, Kumrek, East Sikkim, India
13. Cachet Pharmaceuticals Private Limited, Baddi, Himachal Pradesh, India
14. Alkem Labs Ltd, Unit 5, South Sikkim, India
15. Alkem Labs Ltd., S.E.Z., Indore, Madhya Pradesh, India
16. Enzene Biosciences Limited, Chakan, Pune, Maharashtra, India

MAJOR RESEARCH CENTRES

1. R&D Centre, MIDC, Taloja, Maharashtra, India
2. R&D Centre, Mandva, Gujarat, India
3. Enzene Biosciences Limited, T-Block, MIDC, Bhosari, Pune, Maharashtra, India
4. Enzene Biosciences Limited, MIDC, Bhosari, Pimpri-Chinchwad, Pune, Maharashtra, India
5. S&B Pharma LLC., California, U.S.A.
6. S&B Pharma LLC., Missouri, U.S.A.




Remembering those we lost to COVID-19

COVID-19 has brought a great deal of hardship, claiming innumerable lives and causing widespread grief. Despite our best efforts to keep our people safe, the pandemic has unfortunately caused deaths within Alkem as well. We lost some of our team members due to this dreadful virus. This loss has been very tragic, and on behalf of Alkem, we pay our humble last respects to the departed souls and offer our deepest condolences to their bereaved families.

Sadly, many of our team members have also lost their near and dear ones to COVID-19. Our sincere sympathies are with those who may have lost family or friends. The pain that they are going through is unfathomable and our hearts go out to them. May they find the courage to come to terms with this unexpected and devastating loss.

The pandemic has had a profound impact on our world. At Alkem, we remain committed to supporting our people and other stakeholders that have suffered because of COVID-19. Together we shall overcome.







Remembering Late Mr. Dhananjay Kumar Singh

Our highly respected Joint Managing Director Mr. Dhananjay Kumar Singh passed away on 28th October, 2021.

Mr. Dhananjay Kumar Singh served our Board for more than three decades. During his illustrious tenure, he contributed immensely to multiple facets of our business, including Domestic Operations, Distribution & Logistics, Human Resources, Legal, Secretarial & Compliance, among others.

Alkem benefited tremendously from Mr. Dhananjay Kumar Singh's rich experience in the pharmaceutical industry. He was a leader who gave thought and shape to the future direction of our Company, which was founded by his family.

A truly impactful, selfless and dedicated leader, Mr. Dhananjay Kumar Singh's passing away is a huge loss to Alkem. Our best tribute to him will be to work hard together to take Alkem to greater heights.

May his soul rest in eternal peace.



What's Inside...

1 Corporate Overview

About Alkem _06
Recapturing the Journey _08
Chairman's Message _10
Letter from the Managing Director _12
Board Profile _14
Key Financial Highlights _16
Environment, Health and Safety _18
Leading Talent Towards Excellence and Growth _23
Enriching communities Enhancing lives _28

2 Statutory Reports

Management Discussion & Analysis _32
Directors' Report _52
Corporate Governance Report _74
Business Responsibility Report _94

3 Financial Statements

STANDALONE

Independent Auditor's Report _102
Balance Sheet _114
Statement of Profit and Loss _115
Statement of Changes in Equity _116
Statement of Cash Flow _117
Notes _119

CONSOLIDATED

Independent Auditor's Report _168
Balance Sheet _176
Statement of Profit and Loss _177
Statement of Changes in Equity _178
Statement of Cash Flow _180
Notes _182

Notice _239

Quantitative Highlights for FY 2021-22

₹ 106,342 Mn
Revenue from Operations

₹ 20,529 Mn
EBITDA

₹ 16,456 Mn
Profit After Tax

₹ 137.63
Earnings Per Share

₹ 43.3 Bn
Market Capitalisation[#]

[#]As of 31st March, 2022



To view this report online,
please visit: www.alkemlabs.com

Enhancing Lives

Longer | Better | Fuller



For nearly five decades, Alkem has stayed dedicated to the purpose of enhancing lives through high-quality, affordable solutions. Underpinned by a robust portfolio across multiple therapeutic categories, the Company solves for a diverse breadth of health conditions. Investments continue to be made in bringing innovative solutions to the market for addressing unmet medical needs.

Alkem has consistently expanded its geographic reach over the years. By making available its products around the world, the underlying objective is to improve patient care and health access across markets. Even in the uncertain times brought about by the pandemic, the Company has maintained continuity in delivering its products across India and beyond.

While new products bring new hope, it is often necessary to collaborate with other innovation-focussed organisations to bring these novel treatments to market. United by the shared purpose of enhancing lives, Alkem recently entered into collaborations with global universities and medical research institutions. These collaborations open up new possibilities for advancing the research and commercialisation of impactful medical technologies for patients.

Alkem is driven by the objective of improving healthcare outcomes. Leveraging its strong industry experience, robust quality standards, and proven capabilities in research, manufacturing and distribution, it remains focussed on making valuable contributions in healthcare that will enhance the quality of life – helping people live longer, better and fuller.

About Alkem

Established in 1973, Alkem Laboratories is among India's leading global pharmaceutical companies. The Company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.

MULTI-PRODUCT PORTFOLIO

- Branded Generics
- Generic Drugs
- Active Pharmaceutical Ingredients
- Nutraceuticals
- Biosimilars

Vision

To achieve value-driven leadership in the Indian Healthcare Industry and beyond through:

Quality that is infinite

Service that cares

Hard work that endures



Enhancing lives around the world

Alkem products serve patients and customers in more than 40 countries. The US is the second-largest market for the Company after India. The other key markets include Australia, Chile, Philippines, Kazakhstan, Europe and East Africa. The Company's global operations are supported by state-of-the-art manufacturing and R&D facilities spread across India and the US, which make high-quality healthcare products available, affordable and accessible.

Map not to scale. For illustrative purposes only.

Countries
>40

Employees
16,500+*

Manufacturing Facilities
19

6 R&D Centres driven by **+500** scientists


**Alkem Standalone basis*



Manufacturing Facilities




R&D Facilities




Operating Revenues by Market


India
₹ 75,266 Mn



US
₹ 23,291 Mn



Other
International
Markets
₹ 7,785 Mn



INDIA OPERATIONS

Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company is a leading player in the acute therapeutic segment and a fast-growing player in the chronic therapeutic segment. India operations are underpinned by a robust sales and distribution network and extensive brand building and marketing efforts.

800+
brands

#1*
rank in the
Anti-Infective
segment
for over 15 years

#3*
rank in Gastro-
intestinal
and Analgesic
therapy
segments

6*
brands featuring amongst the top
100 pharmaceutical brands

12
brands with annual
sales of more
than ₹ 1 billion

>10,000**
medical
representatives

7,000+
stockists

60+
sales depots and
CFAs

*Source: IQVIA data, March 2022

**Excluding managers and including Indchemie and Cachet

INTERNATIONAL OPERATIONS

The Company's International business, built on a strong platform of a large and growing product pipeline, is a core part of its growth. These products are distributed through the Company's own sales and commercial infrastructure. Product in-licensing and out-licensing opportunities are also being pursued in international markets to leverage the Company's established strengths.

163
cumulative
Abbreviated New
Drug Application
(ANDA) filings with
the US FDA

>1,100
filings across
various
international
markets

123
cumulative ANDA
approvals from the
US FDA

6
US FDA approved
facilities in India
and US

Recapturing the Journey

Since its inception, Alkem has made significant investments in its capabilities for developing and manufacturing high-quality healthcare products. In this illustrious journey, rewarding milestones have been achieved, emboldening the Company to remain focussed on the purpose of enhancing lives.



1973

Inception of Alkem Laboratories Limited



1978

First manufacturing unit established at Taloja near Mumbai



1992

Second manufacturing facility established at Mandva, Gujarat, which was converted into an API facility in 2005



2003

First research and development facility established at Taloja



2006

Taxim became India's first anti-infective drug to surpass annual sales figure of ₹ 1 billion in the domestic market



2011

Acquired Enzene Biosciences, a company engaged in the development of biosimilars in India



2010

Acquired Ascend Laboratories, a pharmaceutical company in the US



2009

Received the first ANDA approval in the US for the drug Amlodipine



2007

Filed the first ANDA in the US for the drug Amlodipine